4Moving Biotech Raises €12M for OA Drug Development
Lille & Paris, France — February 10, 2026: 4Moving Biotech (4MB), a clinical-stage biotechnology company and spin-off of 4P-Pharma,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Lille & Paris, France — February 10, 2026: 4Moving Biotech (4MB), a clinical-stage biotechnology company and spin-off of 4P-Pharma,...
Florham Park, New Jersey | December 22, 2025 — Celularity Inc., a regenerative and cellular medicine company focused on...
Vancouver, British Columbia, December 18, 2025 — Restart Life Sciences Corp., a Canadian-based life sciences company, has successfully closed...
